Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Eli Lilly and Company
Boehringer Ingelheim
National Cancer Institute (NCI)
Montefiore Medical Center
Montefiore Medical Center
Astellas Pharma Inc
Seagen Inc.
USWM, LLC (dba US WorldMeds)
Seagen Inc.
Pfizer
Turning Point Therapeutics, Inc.
Conjupro Biotherapeutics, Inc.
Abramson Cancer Center at Penn Medicine
Pfizer
EpiBiologics
Pfizer
Dragonfly Therapeutics
Centre Oscar Lambret
PMV Pharmaceuticals, Inc
Hoffmann-La Roche
Hoffmann-La Roche
Aktis Oncology, Inc.
University of California, Irvine
ViroMissile, Inc.
Duke University
AstraZeneca
Tizona Therapeutics, Inc
M.D. Anderson Cancer Center
ALX Oncology Inc.
Betta Pharmaceuticals Co., Ltd.
University of Colorado, Denver
Karolinska University Hospital
UNC Lineberger Comprehensive Cancer Center
Daiichi Sankyo
SN BioScience
Oscotec Inc.
Kidney Cancer Research Bureau
Perspective Therapeutics
Second Life Therapeutics
Onchilles Pharma Inc
Boehringer Ingelheim
M.D. Anderson Cancer Center
Eli Lilly and Company
Varian, a Siemens Healthineers Company
Novartis
UNICANCER
Inhibrx Biosciences, Inc
Varian, a Siemens Healthineers Company
I-Mab Biopharma US Limited